Global Ophthalmic Suspension Market, By Type of Content (Antibiotic, Antifungal, Antibacterial, Steroids, Non-Steroidal Anti-Inflammatory Drugs, Others), Application (Bacterial Infections, Retinal Disorders, Glaucoma, Allergies, Diabetic Eye Disease, Others), End User (Hospitals, Eye Clinics, Clinics, Pharmacies, Others) – Industry Trends and Forecast to 2029.
Global Ophthalmic Suspension Market Analysis and Size
The market for ophthalmic suspension is estimated to increase rapidly over the forecast period. One of the primary factors driving this market's growth is the rising prevalence of eye illnesses around the world. Also, the growing geriatric population, which is more susceptible to eye illnesses and the rising number of bacterial infection cases in youngsters, would propel the market forward. Furthermore, glaucoma is the world's second leading cause of blindness, according to WHO (2014), which will boost market growth. Therefore, these factors will enhance the demand for ophthalmic suspension technology in the market. Ophthalmic suspension (neomycin and polymyxin B sulphates and hydrocortisone) is a treatment for the eyes' bacterial infections that combine two antibiotics and a steroid. The generic version of ophthalmic suspension is available.
- Data Bridge Market Research analyses that the ophthalmic suspension market is expected to grow at a CAGR of 7.80% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Ophthalmic Suspension Market Definition
Ophthalmic suspension is the word for a suspension that is used to treat eye infections and their symptoms. Antibiotics and a corticosteroid are commonly used in combination for more effective treatment. Ophthalmic suspension treats a variety of bacterial eye infections, including conjunctivitis.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type of Content (Antibiotic, Antifungal, Antibacterial, Steroids, Non-Steroidal Anti-Inflammatory Drugs, Others), Application (Bacterial Infections, Retinal Disorders, Glaucoma, Allergies, Diabetic Eye Disease, Others), End User (Hospitals, Eye Clinics, Clinics, Pharmacies, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
Novartis AG (Switzerland), Allergan (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Sanofi (France), Bayer AG (Germany), Abbott (US), Bausch Health Companies Inc. (Canada), Genentech, Inc. (US), Cirondrugs (USA), Dolvis Bio Pharma Private Limited (India), Jubilant Life Sciences Limited (Noida), ENTOD INTERNATIONAL (UK), Akums (India), FDC (India),Carl-Zeiss AG (Germany), VxP Pharma, Inc. (US), Lubrizol Life Science (US), Maya Biotech Private Limited (India), Dev Life Corporation (India)
Ophthalmic Suspension Market Dynamics
- Increasing prevalence of eye diseases '
The rising prevalence of eye diseases across the globe will cushion the market's growth rate. The increase in the number of bacterial infection cases in children will enhance the demand for the ophthalmic suspension market.
- Rise in the incidences of glaucoma and diabetic eye damage
The ophthalmic suspension market is being driven by the increase in glaucoma and diabetic eye damage incidences.
Furthermore, the rising demand for safe ophthalmic suspensions because eyes are more delicate than adult’s adult's eye will act as a major factor influencing the growth of the ophthalmic suspension market. Along with this, increasing urbanization and rising geriatric population are the driving factors accelerating the growth of the ophthalmic suspension market. Also, the rise in the changing lifestyle and increasing expenditure on healthcare infrastructure are the major market drivers that will further escalate the growth of ophthalmic suspension market.
- Growing number of R&D activities
Moreover, the rising number of research and development activities will provide beneficial opportunities for the ophthalmic suspension market growth.
Moreover, growing focus of manufacturers on the adoption of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the ophthalmic suspension market growth during the forecast period.
Restraints/Challenges Global Ophthalmic Suspension Market
- Side-effects associated with ophthalmic suspension '
However, various side-effects associated with the associated with ophthalmic suspension will impede the ophthalmic suspension market's growth rate. Additionally, the loss of patent of blockbuster drugs will hinder the growth rate of ophthalmic suspension market during the forecast period.
On the other hand, the dearth of skilled professionals in under-developed nations will challenge the ophthalmic suspension market. Additionally, emergence of unfavourable conditions due to COVID-19 outbreak and lack of health insurance among population will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This ophthalmic suspension market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ophthalmic suspension market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Ophthalmic Suspension Market
The sickness has expanded to practically every country on the planet since the COVID-19 viral outbreak in December 2019, prompting the World Health Organization to declare it a public health emergency. The global consequences of the coronavirus illness 2019 (COVID-19) are already being felt, and the ophthalmic suspension market will be considerably impacted in 2021. Only emergency procedures are conducted at eye clinics or hospitals, and only minor procedures are performed. Because most ophthalmic medications are prescription drugs that cannot be purchased without a doctor's visit, the market is anticipated to suffer as a result of the outbreak.
- In March 2021, Indoco had announced the launch of Brinzolamide Ophthalmic Suspension 1% in U. S. it is the first generic version of AZOPT by Teva Pharmaceuticals. It is used to treat ocular hypertension and open-angle glaucoma, which cause high pressure inside the eye. Brinzolamide 1 percent Ophthalmic Suspension works by reducing the quantity of fluid in the eye.
Global Ophthalmic Suspension Market Scope
The ophthalmic suspension market is segmented on the basis of type of content, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type of Content
- Non-Steroidal Anti-Inflammatory Drugs
On the basis of type of content, the ophthalmic suspension market is segmented into antibiotic, antifungal, antibacterial, steroids, non-steroidal anti-inflammatory drugs and others.
- Bacterial Infections
- Retinal Disorders
- Diabetic Eye Disease
Based on application, the ophthalmic suspension market is segmented into bacterial infections, retinal disorders, glaucoma, allergies, diabetic eye disease and others. Retinal disorder has further been segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital x-linked retinoschisis, and others.
- Eye Clinics
The end user segment of ophthalmic suspension market is segmented into hospitals, eye clinics, clinics, pharmacies and others.
Ophthalmic Suspension Market Regional Analysis/Insights
The ophthalmic suspension market is analysed and market size insights and trends are provided by country, type of content, application and end user as referenced above.
The countries covered in the ophthalmic suspension market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the ophthalmic suspension market because of the increasing incidences of eye related diseases and presence of major key players in this region. Additionally, growing demand for new ophthalmic suspension for its treatment will flourish the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to rising government support for research and development in healthcare domain in this region. Along with this, increasing number of ophthalmic clinics and surging prevalence of eye-related diseases will flourish the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The ophthalmic suspension market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for ophthalmic suspension market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the ophthalmic suspension market. The data is available for historic period 2010-2020.
Competitive Landscape and Ophthalmic Suspension Market Share Analysis
The Ophthalmic suspension market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ophthalmic suspension market.
Some of the major players operating in the ophthalmic suspension market are:
- Novartis AG (Switzerland)
- Allergan (Ireland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Merck & Co., Inc. (US)
- Sanofi (France)
- Bayer AG (Germany)
- Abbott (US)
- Bausch Health Companies Inc. (Canada)
- Genentech, Inc. (US)
- Cirondrugs (USA)
- Dolvis Bio Pharma Private Limited (India)
- Jubilant Life Sciences Limited (Noida)
- ENTOD INTERNATIONAL (UK)
- Akums (India)
- FDC (India)
- Carl-Zeiss AG (Germany)
- VxP Pharma, Inc. (US)
- Lubrizol Life Science (US)
- Maya Biotech Private Limited (India)
- Dev Life Corporation (India)
Research Methodology : Global Ophthalmic Suspension Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-ophthalmic-suspension-market